Home » Neoprobe’s Phase III Lymphoseek Study Achieves Positive Results
Neoprobe’s Phase III Lymphoseek Study Achieves Positive Results
Neoprobe Corporation, a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that a multicenter Phase 3 study of Lymphoseek has reached the accrual of 203 lymph nodes, the study’s primary accrual objective.
iStockAnalyst.com
iStockAnalyst.com
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May